Background: The challenging market access of high-cost one-time curative therapies has
inspired the development of alternative reimbursement structures, such as outcome-based …

Aim: Regenerative medicines (RMs) are expected to transform the treatment paradigm of
rare, life-threatening diseases, while substantial challenges impede its market access. This …

The concept of a reference case, first proposed by the US Panel on Cost-Effectiveness in
Health and Medicine, has been used to specify the required methodological features of …

Recently licensed cell and gene therapies have promising but highly uncertain clinical
benefits. They are entering the market at very high prices, with the latest entrants costing …

The pharmaceutical industry is almost boundless in its ability to supply new drug therapies,
but how does one decide which are the best medicines to use within restricted budgets …

The reimbursement of expensive, innovative therapies poses a challenge to healthcare
systems. This study investigated the feasibility of managed entry agreements (MEAs) for …

Objectives Medical devices are potentially good candidates for coverage with evidence
development (CED) schemes, as clinical data at market entry are often sparse and (cost-) …

Payers are concerned that one-off “cures” bring great uncertainty with the consequential risk
of incorrect adoption decisions, and significant budget impact from large one-off payments …

Can disruption happen when no one notices? Disruptive technologies and processes are
fundamentally starting to up-end how medicines and health systems benefit patients but the …

Background We have seen significant advancement in a range of health technologies, some
with transformative or curative potential. Nevertheless, it is often unclear how global health …